Clinical Trial Update: Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk [Phase 3]

View source ↗

Summary

The Phase 3 study LX201 for prevention of corneal allograft rejection in high-immunological-risk subjects has been terminated. The update does not present trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Graft Rejection

Drugs mentioned

• LX201

Snippet

Sponsor: Lux Biosciences, Inc. | Conditions: Corneal Diseases, Cornea Transplant | Phase 3 | Status: TERMINATED